Skip to content

Amylyx Pharmaceuticals

US · AMLX #2392 by market cap Listed 2022
26.02 -0.18 -0.69%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of therapies for diseases with significant unmet medical need, with an emphasis on endocrine and neurodegenerative disorders. Its program, avexitide, is a once-daily GLP-1 receptor antagonist being developed for the treatment of post-bariatric hypoglycemia. Amylyx’s pipeline also includes investigational programs targeting Wolfram syndrome and amyotrophic lateral sclerosis (ALS). The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Founded
2013
Employees
136
Headquarters
Cambridge, Massachusetts, United States of America
Fiscal year end
12-31
Website
amylyx.com

Company profile

Exchange
US
Symbol
AMLX
Market-cap rank
#2392
Listing date
2022-01-07
Market cap
3.35B
Float cap
2.88B
Shares out
128.56M
Float shares
110.59M

Sectors & themes

Browse all sectors & themes

Quote time 2026-11-20 20:02:24 · For reference only, not investment advice and not tailored to your situation.

Amylyx Pharmaceuticals discussion 0 comments

Add a comment